



Daniel Reimer

Contact

Daniel Reimer

Publications (8)

Wolf D, Reimer D, Hartmann G, Sopper S, Sprung S, Marth C, Wieser V, Zeimet A, Fiegl H, Bösch M. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. *Int J Cancer* 2019

Hatina J, Bösch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet A. Ovarian Cancer Stem Cell Heterogeneity. *Adv Exp Med Biol* 2019; 1139:201-221.

Bösch M, Reimer D, Wolf D, Hatina J, Rössler J, Wiedemair A, Fiegl H, Marth C, Sopper S, Zeimet A. Evaluation of Vav3.1 as prognostic marker in endometrial cancer. *J Cancer Res Clin Oncol* 2018; 144:2067-2076.

Bösch M, Reimer D, Sopper S, Wolf D, Zeimet A. (Iso-)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer. *Oncologist* 2018; 23:757-759.

Reimer D, Hackl H, Parson W, Altevogt P, Hatina J, Sopper S, Marth C, Wolf D, Bösch M, Zeimet A. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response. *Int J Cancer* 2017; 142:1640-1651.

Bösch M, Sopper S, Zeimet A, Reimer D, Gastl G, Ludwig B, Wolf D. Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche. *Biochim Biophys Acta* 2016; 1866:276-289.

Bösch M, Wolf D, Hatina J, Spoeck F, Parson W, Gastl G, Schmidt S, Reimer D, Zeimet A, Sopper S. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. *Oncotarget* 2014; 5:7027-39.

Bösch M, Reimer D, Rumpold H, Zeimet A, Sopper S, Wolf D. DyeCycle Violet used for side population detection is a substrate of P-glycoprotein. *Cytometry A* 2012; 81:517-22.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch